The sialogogic effect of
SNI-2011, a novel
muscarinic receptor agonist, (+/-)-cis-2-methylspilo [1,3-oxathiolane-5,3'-
quinuclidine] hydrochloride, hemihydrate, was compared with that of
pilocarpine hydrochloride in a dose range in which the two
muscarinic agonists exhibited approximately similar efficacy in eliciting salivation.
Pilocarpine (0.66-2.0 mg/kg, i.d.) induced a marked but short-lasting salivation in rats, whereas the salivation induced by
SNI-2011 (20-60 mg/kg, i.d.) lasted 1.4- to 1.8-fold longer. In dogs, the sialogogic effect of
SNI-2011(1-3 mg/kg, i.v.) also lasted about 2-fold longer than that of
pilocarpine (0.1-0.3 mg/kg, i.v.). The plasma
SNI-2011 level that caused salivation at a rate of 0.4 ml/min was about 100 ng/ml and higher rates of salivation (over 0.4 ml/min) induced by 1 mg/kg
SNI-2011 lasted for about 90 min in dogs. The plasma
pilocarpine level that caused salivation at a rate of 0.4 ml/min was about 25 ng/ml and the higher rate of salivation (over 0.4 ml/min) induced by 0.1 mg/kg
pilocarpine lasted only for 20 min in dogs. Effective plasma levels of
SNI-2011 persisted longer than those of
pilocarpine. These results indicate that
SNI-2011 may be useful in the treatment of
xerostomia because of its long-lasting sialogogic action.